🔎 Trials Near Me

Beranda › Kanker Paru Sel Kecil › North Carolina

Uji klinis Kanker Paru Sel Kecil di North Carolina

16 studi untuk Kanker Paru Sel Kecil mencari peserta di lokasi di North Carolina.

Kota di North Carolina

Teks studi resmi (Bahasa Inggris)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Duke University, Durham
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  • Cape Fear Valley Cancer Center, Fayetteville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07472517

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  • GSK Investigational Site, Wilson
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07099898

DESTINY-PANTUMOUR04

  • Research Site, Durham
  • Research Site, Wilson
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  • FirstHealth of the Carolinas- Speciality Center /ID# 279857, Pinehurst
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07365241

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  • Duke Cancer Center Durham, Durham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07488676

Study of Trilaciclib and Lurbinectidin

  • Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05578326

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

  • Duke Cancer Institute, Durham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07325136

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

  • Clinical Trial Site, Huntersville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07749586

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Duke University Medical Center, Durham
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT05652686

Tempus Small Cell Lung Cancer Observational Study (Sculptor)

  • University of North Carolina, Chapel Hill
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT05257551

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

  • FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Mar 2026 · NCT06769126

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

  • Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Mar 2026 · NCT06681220

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  • Carolina BioOncology Institute, Huntersville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT07030257

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

  • Lineberger Comprehensive Cancer Center, Chapel Hill
Menerima pesertaFase awal 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT05620342

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.